What is a key box warning for Valsartan/Sacubitril?

Valsartan/Sacubitril, marketed as Entresto, carries a significant boxed warning regarding pregnancy. This warning emphasizes the risks associated with using this medication during pregnancy, particularly the potential for fetal harm or death. Use of this drug is contraindicated during pregnancy due to its effects on the renin-angiotensin system, which can adversely affect fetal development. This is crucial information for healthcare providers and patients, as it guides the safe prescribing of the drug and emphasizes the importance of using effective contraception in women of childbearing age.

The boxed warning exists to highlight the potential risks and to encourage necessary precautions in prescribing practices. Understanding this information is vital for ensuring patient safety, particularly in populations where pregnancy is a consideration.